000140487 001__ 140487
000140487 005__ 20240109101331.0
000140487 0247_ $$2doi$$a10.1007/s00115-018-0571-8
000140487 0247_ $$2pmid$$apmid:30073487
000140487 0247_ $$2ISSN$$a0028-2804
000140487 0247_ $$2ISSN$$a1433-0407
000140487 0247_ $$2altmetric$$aaltmetric:46026894
000140487 037__ $$aDZNE-2020-06809
000140487 041__ $$ager
000140487 082__ $$a610
000140487 1001_ $$aKnauss, S.$$b0
000140487 245__ $$a[Neurological side effects of checkpoint inhibitors].
000140487 260__ $$aHeidelberg$$bSpringer$$c2019
000140487 264_1 $$2Crossref$$3online$$bSpringer Science and Business Media LLC$$c2018-08-02
000140487 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2019-02-01
000140487 3367_ $$2DRIVER$$aarticle
000140487 3367_ $$2DataCite$$aOutput Types/Journal article
000140487 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1704791226_29463
000140487 3367_ $$2BibTeX$$aARTICLE
000140487 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140487 3367_ $$00$$2EndNote$$aJournal Article
000140487 520__ $$aIn recent years the treatment of many tumor entities has been revolutionized by the use of modern immunotherapies with checkpoint inhibitors; however, good response rates are contrasted by many immune-mediated side effects. Neurological immune-mediated side effects are rare but often severe complications of checkpoint inhibitor treatment.A systematic search in the PubMed and Web of Sciences databases was carried out for case reports and studies on neurological side effects during checkpoint inhibitor treatment.A total of 42 articles on neurological side effects of checkpoint inhibitors with a total of 85 reported cases could be identified. The most frequently reported neurological side effects were myopathies, neuropathies, diseases of the neuromuscular endplates and encephalitides. Among those, encephalitides and myopathies with accompanying myocarditis were associated with the highest morbidity and mortality.Against the background of a rapidly increasing use of checkpoint inhibitors, this article provides an overview of currently available reports on the clinical courses of neurological side effects. Controlled studies on the treatment of neurological side effects are lacking. From case studies it can be assumed that early steroid treatment increases the probability of a complete remission of neurological symptoms. Typical symptom constellations must therefore be rapidly recognized and an immunosuppressive treatment must be initiated.
000140487 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000140487 542__ $$2Crossref$$i2018-08-02$$uhttp://www.springer.com/tdm
000140487 588__ $$aDataset connected to CrossRef, PubMed,
000140487 650_7 $$2NLM Chemicals$$aAntineoplastic Agents, Immunological
000140487 650_2 $$2MeSH$$aAntineoplastic Agents, Immunological: adverse effects
000140487 650_2 $$2MeSH$$aAntineoplastic Agents, Immunological: therapeutic use
000140487 650_2 $$2MeSH$$aDrug-Related Side Effects and Adverse Reactions
000140487 650_2 $$2MeSH$$aHumans
000140487 650_2 $$2MeSH$$aImmunotherapy
000140487 650_2 $$2MeSH$$aNeoplasms: therapy
000140487 650_2 $$2MeSH$$aNervous System Diseases: chemically induced
000140487 7001_ $$aGinesta Roque, L.$$b1
000140487 7001_ $$aHühnchen, P.$$b2
000140487 7001_ $$aHeinzerling, L.$$b3
000140487 7001_ $$0P:(DE-HGF)0$$aBöhmerle, W.$$b4$$eCorresponding author
000140487 7001_ $$0P:(DE-2719)2811033$$aEndres, M.$$b5$$eLast author$$udzne
000140487 77318 $$2Crossref$$3journal-article$$a10.1007/s00115-018-0571-8$$b : Springer Science and Business Media LLC, 2018-08-02$$n2$$p138-147$$tDer Nervenarzt$$v90$$x0028-2804$$y2018
000140487 773__ $$0PERI:(DE-600)1462945-8$$a10.1007/s00115-018-0571-8$$gVol. 90, no. 2, p. 138 - 147$$n2$$p138-147$$q90:2<138 - 147$$tDer Nervenarzt$$v90$$x0028-2804$$y2019
000140487 8564_ $$uhttps://pub.dzne.de/record/140487/files/DZNE-2020-06809.pdf
000140487 8564_ $$uhttps://pub.dzne.de/record/140487/files/DZNE-2020-06809.pdf?subformat=pdfa$$xpdfa
000140487 909CO $$ooai:pub.dzne.de:140487$$pVDB
000140487 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811033$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000140487 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000140487 9141_ $$y2019
000140487 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000140487 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000140487 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000140487 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000140487 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000140487 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000140487 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNERVENARZT : 2021$$d2022-11-12
000140487 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-12
000140487 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-12
000140487 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-12
000140487 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lInterdisciplinary Dementia Research$$x0
000140487 980__ $$ajournal
000140487 980__ $$aVDB
000140487 980__ $$aI:(DE-2719)1811005
000140487 980__ $$aUNRESTRICTED
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1177/1078155215572932$$o10.1177/1078155215572932
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/CJI.0b013e318193a206$$o10.1097/CJI.0b013e318193a206
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1136/practneurol-2012-000447$$o10.1136/practneurol-2012-000447
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2016.66.6552$$o10.1200/JCO.2016.66.6552
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/COC.0000000000000239$$o10.1097/COC.0000000000000239
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/s13104-015-1283-9$$o10.1186/s13104-015-1283-9
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/MD.0000000000007350$$o10.1097/MD.0000000000007350
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1158/2326-6066.CIR-15-0035$$o10.1158/2326-6066.CIR-15-0035
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S1470-2045(15)70122-1$$o10.1016/S1470-2045(15)70122-1
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ejso.2016.07.145$$o10.1016/j.ejso.2016.07.145
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/CJI.0b013e31827807dd$$o10.1097/CJI.0b013e31827807dd
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/ana.24715$$o10.1002/ana.24715
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1177/1352458514549403$$o10.1177/1352458514549403
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.nmd.2017.01.002$$o10.1016/j.nmd.2017.01.002
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ejca.2016.12.038$$o10.1016/j.ejca.2016.12.038
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/CCO.0000000000000358$$o10.1097/CCO.0000000000000358
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/s40425-016-0152-y$$o10.1186/s40425-016-0152-y
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa1609214$$o10.1056/NEJMoa1609214
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2013.51.1683$$o10.1200/JCO.2013.51.1683
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1146/annurev.immunol.26.021607.090331$$o10.1146/annurev.immunol.26.021607.090331
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/cas.12961$$o10.1111/cas.12961
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1055/s-0033-1355337$$o10.1055/s-0033-1355337
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa1504030$$o10.1056/NEJMoa1504030
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1634/theoncologist.2016-0487$$o10.1634/theoncologist.2016-0487
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mus.25141$$o10.1002/mus.25141
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3389/fimmu.2018.00108$$o10.3389/fimmu.2018.00108
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/neuonc/nou001$$o10.1093/neuonc/nou001
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mus.24648$$o10.1002/mus.24648
000140487 999C5 $$2Crossref$$oO Maeda 2016$$y2016
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jacc.2018.02.037$$o10.1016/j.jacc.2018.02.037
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMc1515584$$o10.1056/NEJMc1515584
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jns.2014.06.023$$o10.1016/j.jns.2014.06.023
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mus.23830$$o10.1002/mus.23830
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/annonc/mdw181$$o10.1093/annonc/mdw181
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/CMR.0000000000000310$$o10.1097/CMR.0000000000000310
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00415-008-0783-0$$o10.1007/s00415-008-0783-0
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3109/09273948.2014.1001858$$o10.3109/09273948.2014.1001858
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mus.25163$$o10.1002/mus.25163
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S1470-2045(15)00083-2$$o10.1016/S1470-2045(15)00083-2
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1158/1078-0432.CCR-12-3080$$o10.1158/1078-0432.CCR-12-3080
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1155/2017/1093858$$o10.1155/2017/1093858
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1136/bcr-2016-215012$$o10.1136/bcr-2016-215012
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1159/000477162$$o10.1159/000477162
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.2340/00015555-2548$$o10.2340/00015555-2548
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mus.25212$$o10.1002/mus.25212
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1177/1010428317695013$$o10.1177/1010428317695013
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/jjco/hyv158$$o10.1093/jjco/hyv158
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/annonc/mdw558$$o10.1093/annonc/mdw558
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/MAJ.0000000000000584$$o10.1097/MAJ.0000000000000584
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/CJI.0000000000000190$$o10.1097/CJI.0000000000000190
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/jjco/hyw090$$o10.1093/jjco/hyw090
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/CJI.0000000000000177$$o10.1097/CJI.0000000000000177
000140487 999C5 $$2Crossref$$o
000140487 999C5 $$2Crossref$$oU.S. Food and Drug Administration 2017$$y2017
000140487 999C5 $$2Crossref$$oDepartment of Health Common terminology criteria for adverse events (CTCAE) v5.0 2017$$tCommon terminology criteria for adverse events (CTCAE) v5.0$$y2017
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1126/science.aad1329$$o10.1126/science.aad1329
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1371/journal.pone.0053745$$o10.1371/journal.pone.0053745
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S1470-2045(15)70076-8$$o10.1016/S1470-2045(15)70076-8
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1001/jamaneurol.2016.1399$$o10.1001/jamaneurol.2016.1399
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/CJI.0b013e318156e47e$$o10.1097/CJI.0b013e318156e47e
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mus.25055$$o10.1002/mus.25055
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3171/2016.8.PEDS16326$$o10.3171/2016.8.PEDS16326
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ejca.2016.02.024$$o10.1016/j.ejca.2016.02.024
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s10637-011-9787-1$$o10.1007/s10637-011-9787-1
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1634/theoncologist.2016-0366$$o10.1634/theoncologist.2016-0366
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMra1514296$$o10.1056/NEJMra1514296
000140487 999C5 $$2Crossref$$oClinicalTrials.gov MDX-010 antibody, MDX-1379 melanoma vaccine, or MDX-010/MDX-1379 combination treatment for patients with unresectable or metastatic melanoma 2011$$tMDX-010 antibody, MDX-1379 melanoma vaccine, or MDX-010/MDX-1379 combination treatment for patients with unresectable or metastatic melanoma$$y2011
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Efficacy study of Ipilimumab versus placebo to prevent recurrence after complete resection of high risk stage III melanom 2017$$tEfficacy study of Ipilimumab versus placebo to prevent recurrence after complete resection of high risk stage III melanom$$y2017
000140487 999C5 $$2Crossref$$oClinicalTrials.gov A study to compare BMS-936558 to the physician’s choice of either dacarbazine or carboplatin and paclitaxel in advanced melanoma patients that have progressed following anti-CTLA-4 therapy (checkmate 037) 2017$$tA study to compare BMS-936558 to the physician’s choice of either dacarbazine or carboplatin and paclitaxel in advanced melanoma patients that have progressed following anti-CTLA-4 therapy (checkmate 037)$$y2017
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study of Nivolumab (BMS-936558) compared with dacarbazine in untreated, unresectable, or metastatic melanoma (checkmate 066) 2017$$tStudy of Nivolumab (BMS-936558) compared with dacarbazine in untreated, unresectable, or metastatic melanoma (checkmate 066)$$y2017
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Trial of nivolumab vs therapy of investigator’s choice in recurrent or metastatic head and neck carcinoma (checkmate 141) 2016$$tTrial of nivolumab vs therapy of investigator’s choice in recurrent or metastatic head and neck carcinoma (checkmate 141)$$y2016
000140487 999C5 $$2Crossref$$oClinicalTrials.gov A study of pembrolizumab (MK-3475) in participants with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (MK-3475-059/KEYNOTE-059) 2017$$tA study of pembrolizumab (MK-3475) in participants with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (MK-3475-059/KEYNOTE-059)$$y2017
000140487 999C5 $$2Crossref$$oClinicalTrials.gov A study of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK-3475-045/KEYNOTE-045) 2017$$tA study of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK-3475-045/KEYNOTE-045)$$y2017
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Nivolumab combined with Ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (checkmate 214) 2018$$tNivolumab combined with Ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (checkmate 214)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated metastatic non-squamous NSCLC (checkmate057) 2018$$tStudy of BMS-936558 (Nivolumab) compared to docetaxel in previously treated metastatic non-squamous NSCLC (checkmate057)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov [Internet] Bethesda (MD): National Library of Medicine (US) Study of nivolumab (BMS-936558) vs. everolimus in pre-treated advanced or metastatic clear-cell renal cell carcinoma (checkmate 025) 2018$$tStudy of nivolumab (BMS-936558) vs. everolimus in pre-treated advanced or metastatic clear-cell renal cell carcinoma (checkmate 025)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Phase 3 study of nivolumab or nivolumab plus Ipilimumab versus Ipilimumab alone in previously untreated advanced melanoma (checkmate 067) 2018$$tPhase 3 study of nivolumab or nivolumab plus Ipilimumab versus Ipilimumab alone in previously untreated advanced melanoma (checkmate 067)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov An Immuno-therapy study to evaluate the effectiveness, safety and tolerability of nivolumab or nivolumab in combination with other agents in patients with advanced liver cancer (checkmate040) 2018$$tAn Immuno-therapy study to evaluate the effectiveness, safety and tolerability of nivolumab or nivolumab in combination with other agents in patients with advanced liver cancer (checkmate040)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov An investigational immuno-therapy study of nivolumab, and nivolumab in combination with other anti-cancer drugs, in colon cancer that has come back or has spread (checkmate142) 2018$$tAn investigational immuno-therapy study of nivolumab, and nivolumab in combination with other anti-cancer drugs, in colon cancer that has come back or has spread (checkmate142)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov A study of nivolumab in participants with metastatic or unresectable bladder cancer 2018$$tA study of nivolumab in participants with metastatic or unresectable bladder cancer$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study of nivolumab in patients with classical Hodgkin’s lymphoma (registrational) (checkmate 205) 2018$$tStudy of nivolumab in patients with classical Hodgkin’s lymphoma (registrational) (checkmate 205)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Efficacy study of nivolumab compared to Ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb/c or stage IV melanoma (checkmate 238) 2018$$tEfficacy study of nivolumab compared to Ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb/c or stage IV melanoma (checkmate 238)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) (checkmate 017) 2018$$tStudy of BMS-936558 (Nivolumab) compared to docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) (checkmate 017)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study to evaluate the safety and efficacy of two different dosing schedules of pembrolizumab (MK-3475) compared to Ipilimumab in participants with advanced melanoma (MK-3475-006/KEYNOTE-006) 2018$$tStudy to evaluate the safety and efficacy of two different dosing schedules of pembrolizumab (MK-3475) compared to Ipilimumab in participants with advanced melanoma (MK-3475-006/KEYNOTE-006)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) 2018$$tStudy of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475-012/KEYNOTE-012) 2018$$tStudy of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475-012/KEYNOTE-012)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) 2018$$tStudy of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475-028/KEYNOTE-28) 2018$$tStudy of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475-028/KEYNOTE-28)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study of pembrolizumab (MK-3475) as monotherapy in participants with previously-treated locally advanced unresectable or metastatic colorectal cancer (MK-3475-164/KEYNOTE-164) 2018$$tStudy of pembrolizumab (MK-3475) as monotherapy in participants with previously-treated locally advanced unresectable or metastatic colorectal cancer (MK-3475-164/KEYNOTE-164)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Phase 2 study of MK-3475 in patients with microsatellite unstable (MSI) tumors 2018$$tPhase 2 study of MK-3475 in patients with microsatellite unstable (MSI) tumors$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study of pembrolizumab (MK-3475) in participants with advanced urothelial cancer (MK-3475-052/KEYNOTE-52) 2018$$tStudy of pembrolizumab (MK-3475) in participants with advanced urothelial cancer (MK-3475-052/KEYNOTE-52)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study of pembrolizumab (MK-3475) in participants with relapsed or refractory classical Hodgkin lymphoma (MK-3475-087/KEYNOTE-087) 2018$$tStudy of pembrolizumab (MK-3475) in participants with relapsed or refractory classical Hodgkin lymphoma (MK-3475-087/KEYNOTE-087)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Study of two doses of pembrolizumab (MK-3475) versus docetaxel in previously treated participants with non-small cell lung cancer (MK-3475-010/KEYNOTE-010) 2018$$tStudy of two doses of pembrolizumab (MK-3475) versus docetaxel in previously treated participants with non-small cell lung cancer (MK-3475-010/KEYNOTE-010)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov A study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed platinum-containing therapy (OAK) 2018$$tA study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed platinum-containing therapy (OAK)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov A study of atezolizumab in participants with locally advanced or metastatic urothelial bladder cancer (cohort 1) 2018$$tA study of atezolizumab in participants with locally advanced or metastatic urothelial bladder cancer (cohort 1)$$y2018
000140487 999C5 $$2Crossref$$oClinicalTrials.gov Avelumab in metastatic or locally advanced solid tumors (JAVELIN solid tumor) 2018$$tAvelumab in metastatic or locally advanced solid tumors (JAVELIN solid tumor)$$y2018
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/eji.201646875$$o10.1002/eji.201646875
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ctrv.2017.01.008$$o10.1016/j.ctrv.2017.01.008
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1158/2326-6066.CIR-15-0141$$o10.1158/2326-6066.CIR-15-0141
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1159/000362614$$o10.1159/000362614
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.20517/2394-4722.2017.41$$o10.20517/2394-4722.2017.41
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/CJI.0000000000000070$$o10.1097/CJI.0000000000000070
000140487 999C5 $$2Crossref$$oU.S. Food and Drug Administration YERVOY highlights of prescribing information 2011$$tYERVOY highlights of prescribing information$$y2011
000140487 999C5 $$2Crossref$$oU.S. Food and Drug Administration BAVENCIO highlights of prescribing information 2017$$tBAVENCIO highlights of prescribing information$$y2017
000140487 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/annonc/mdr028$$o10.1093/annonc/mdr028